Published in Br J Dermatol on August 02, 2014
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors. Biologics (2015) 0.85
Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS One (2015) 0.78
Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face. Case Rep Oncol Med (2015) 0.75
Aggressive basal cell carcinoma of the head and neck: challenges in surgical management. Eur Arch Otorhinolaryngol (2016) 0.75
Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol (1998) 2.17
Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet (1997) 1.98
Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol (2001) 1.86
Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum (1994) 1.64
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology (1997) 1.44
Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ (2009) 1.43
CD30-positive lymphoproliferative disorder in a red tattoo: regional lymphomatoid papulosis type C or pseudolymphoma? Br J Dermatol (2014) 1.38
Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology (1997) 1.24
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res (1995) 1.24
Stabilin-1, a homeostatic scavenger receptor with multiple functions. J Cell Mol Med (2006) 1.22
Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol (2005) 1.22
Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia (2007) 1.21
Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation. J Pathol (1999) 1.18
Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol (2003) 1.16
Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene (2007) 1.15
Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J Pathol (2006) 1.14
Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis. Arch Dermatol Res (1996) 1.13
IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol (2000) 1.11
Kaposi's sarcoma is an important risk factor for survival in HIV-infected patients independent of CD4+ cell count. AIDS (1999) 1.09
UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways. Br J Dermatol (2009) 1.08
Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol (2011) 1.05
The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells. Scand J Immunol (2004) 1.03
Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer (2001) 1.01
[Acquired reactive perforating dermatosis. Successful treatment with allopurinol in 2 cases]. Hautarzt (1999) 1.01
Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer (2001) 1.01
Alternatively activated antigen-presenting cells: molecular repertoire, immune regulation, and healing. Skin Pharmacol Appl Skin Physiol (2001) 1.00
Long-term results after reconstruction of full thickness scalp defects with a dermal regeneration template. J Eur Acad Dermatol Venereol (2009) 0.99
Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res (1998) 0.98
Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol (2002) 0.97
Nickel chloride and cobalt chloride, two common contact sensitizers, directly induce expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule (ELAM-1) by endothelial cells. J Invest Dermatol (1993) 0.97
MHC class II and CD40 play opposing roles in dendritic cell survival. Eur J Immunol (2000) 0.95
Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia (2006) 0.95
A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int J Cancer (1986) 0.95
Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol (2012) 0.94
[Caterpillar dermatitis. An increasing dermatologic problem in warmer regions of Germany]. Hautarzt (2009) 0.93
Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy. Acta Dermatovenerol Alp Pannonica Adriat (2010) 0.93
[Zosteriform lichen aureus]. Hautarzt (1998) 0.92
Metastatic Crohn's disease of the face. J Am Acad Dermatol (1996) 0.91
Expression of basic fibroblast growth factor (bFGF) in Kaposi's sarcoma: an immunohistologic study. J Invest Dermatol (1990) 0.91
1alpha,25-dihydroxyvitamin D3 induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor alpha. J Biol Chem (1997) 0.88
Giant genital variant of folliculosebaceous cystic hamartoma: successful management by CO2 laser and acitretin therapy. Br J Dermatol (2007) 0.88
Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol (2000) 0.87
[Interferon-alpha-induced psoriasis vulgaris]. Hautarzt (1996) 0.87
Differentiation between merkel cell carcinoma and malignant melanoma: An immunohistochemical study. Dermatology (2000) 0.86
Differential susceptibility to CD95 (Apo-1/Fas) and MHC class II-induced apoptosis during murine dendritic cell development. Cell Death Differ (2000) 0.86
Unilateral angiolymphoid hyperplasia with eosinophilia involving the left arm and hand. J Cutan Pathol (1999) 0.85
Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation. Oncogene (2011) 0.85
Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br J Dermatol (2006) 0.85
c-MYC and nodular malignant melanoma. A case report. Cancer (2000) 0.85
Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol (2005) 0.85
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ (2013) 0.85
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol (2012) 0.85
The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers. Br J Dermatol (2008) 0.84
Chronic urticaria, arthralgia, raised erythrocyte sedimentation rate and IgG paraproteinaemia: a variant of Schnitzler's syndrome? Br J Dermatol (1995) 0.83
Evidence of heterogeneity and quantitative differences of the type 1 5alpha-reductase expression in cultured human skin cells--evidence of its presence in melanocytes. J Invest Dermatol (1998) 0.83
Thymidine dinucleotides inhibit contact hypersensitivity and activate the gene for tumor necrosis factor alpha1. J Invest Dermatol (2000) 0.82
MS-1 sinusoidal endothelial antigen is expressed by factor XIIIa+, HLA-DR+ dermal perivascular dendritic cells. Lab Invest (1991) 0.82
Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life. Z Gastroenterol (2013) 0.82
Cutaneous involvement in prelymphomatous angioimmunoblastic lymphadenopathy. J Am Acad Dermatol (1997) 0.82
Guess what! Eruptive vellus hair cysts. Eur J Dermatol (2000) 0.82
Carcinoembryonic antigen and related glycoproteins in psoriasis. Pathobiology (1993) 0.82
Melkersson-Rosenthal syndrome in childhood: a challenge in differential diagnosis and treatment. Br J Dermatol (2000) 0.82
Synopsis on cellular senescence and apoptosis. J Vasc Surg (2001) 0.81
Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia (2001) 0.81
Pseudoexons and regulatory elements in the genomic sequence of the beta-chemokine, alternative macrophage activation-associated CC-chemokine (AMAC)-1. Cytokine (2000) 0.81
P-cadherin expression in Merkel cell carcinomas is associated with prolonged recurrence-free survival. Br J Dermatol (2012) 0.81
Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient. Br J Dermatol (1998) 0.81
Severe course of chronic urticaria, arthralgia, fever and elevation of erythrocyte sedimentation rate: Schnitzler's syndrome without monoclonal gammopathy? Br J Dermatol (2000) 0.80
Nodular and bullous cutaneous mastocytosis of the xanthelasmoid type: case report. Br J Dermatol (2001) 0.80
Simvastatin-induced amyopathic dermatomyositis. Br J Dermatol (2009) 0.80
[Kaposiform HHV-8 negative acroangiodermatitis in chronic venous insufficiency]. Hautarzt (1999) 0.79
Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. Br J Dermatol (2005) 0.79
Vascular endothelial growth factor expression induced by proinflammatory cytokines (interleukin 1 alpha, beta) in cells of the human pilosebaceous unit. Dermatology (1998) 0.79
Identification of the novel differentiation marker MS4A8B and its murine homolog MS4A8A in colonic epithelial cells lost during neoplastic transformation in human colon. Cell Death Dis (2013) 0.79
[Hepatitis C virus-associated dermatoses: a review]. Hautarzt (1999) 0.78
[Granulomatosis disciformis Miescher]. Hautarzt (1998) 0.78
Current status of cutaneous T-cell lymphoma: molecular diagnosis, pathogenesis, therapy and future directions. Onkologie (2003) 0.78
Dissection of macrophage differentiation pathways in cutaneous macrophage disorders and in vitro. Exp Dermatol (1994) 0.78
[Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt (2010) 0.78
Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement. Lancet (1997) 0.78
Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol (2012) 0.77
Long-term extracorporeal photoimmunotherapy for treatment of chronic cutaneous graft-versus-host disease: observations in four patients. Dermatology (1999) 0.77
Persistent telangiectatic erythema associated with an automatic implantable cardioverter defibrillator. Br J Dermatol (1997) 0.77
Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany. J Eur Acad Dermatol Venereol (2014) 0.77
Langerhans cells do not express alternative macrophage activation-associated CC chemokine (AMAC)-1. Res Immunol (1999) 0.77
One-stage reconstruction of deep facial defects with a single layer dermal regeneration template. J Eur Acad Dermatol Venereol (2010) 0.77
Effect of chronic wound fluid on fibroblasts. J Wound Care (1998) 0.77
Topical psoralen photochemotherapy with lethal outcome. Arch Dermatol (2001) 0.76